EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The TLR2/TLR6 ligand FSL-1 mitigates radiation-induced hematopoietic injury in mice and nonhuman primates

W June Brickey iD, David L Caudell iD, Andrew N Macintyre iD, John D Olson iD, Yanwan Dai, Sirui Li iD, Gregory O Dugan, J Daniel Bourland iD, Lisa M O'Donnell iD, Janet A Tooze, Guannan Huang, Shuangshuang Yang und 10 weitere

Proceedings of the National Academy of Sciences · 2023

DOI: 10.1073/pnas.2122178120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2023. Verfasst von W June Brickey und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599. Hauptthemen laut MEDLINE: Toll-Like Receptor 2, Acute Radiation Syndrome. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NCI NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thrombocytopenia, hemorrhage, anemia, and infection are life-threatening issues following accidental or intentional radiation exposure. Since few therapeutics are available, safe and efficacious small molecules to mitigate radiation-induced injury need to be developed. Our previous study showed the synthetic TLR2/TLR6 ligand fibroblast stimulating lipopeptide (FSL-1) prolonged survival and provided MyD88-dependent mitigation of hematopoietic acute radiation syndrome (H-ARS) in mice. Although mice and humans differ in TLR number, expression, and function, nonhuman primate (NHP) TLRs are like those of humans; therefore, studying both animal models is critical for drug development. The objectives of this study were to determine the efficacy of FSL-1 on hematopoietic recovery in small and large animal models subjected to sublethal total body irradiation and investigate its mechanism of action. In mice, we demonstrate a lack of adverse effects, an easy route of delivery (subcutaneous) and efficacy in promoting hematopoietic progenitor cell proliferation by FSL-1. NHP given radiation, followed a day later with a single subcutaneous administration of FSL-1, displayed no adversity but showed elevated hematopoietic cells. Our analyses revealed that FSL-1 promoted red blood cell development and induced soluble effectors following radiation exposure. Cytologic analysis of bone marrow aspirates revealed a striking enhancement of mononuclear progenitor cells in FSL-1-treated NHP. Combining the efficacy of FSL-1 in promoting hematopoietic cell recovery with the lack of adverse effects induced by a single administration supports the application of FSL-1 as a viable countermeasure against H-ARS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Toll-Like Receptor 2Acute Radiation SyndromeHumansMiceAnimalsToll-Like Receptor 6LigandsPrimatesFibroblasts

Stichwörter der Autor:innen

animal modelshematopoiesisinnate immunitymitigatorradiation

Substanzen

Toll-Like Receptor 2Toll-Like Receptor 6LigandsTLR2 protein, humanTLR6 protein, human

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599.
  • Lineberger Comprehensive Cancer Center, Center of Translational Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599.
  • Department of Pathology, Section on Comparative Medicine, Wake Forest University School of Medicine, Winston Salem, NC 27157.
  • Duke Human Vaccine Institute, Department of Medicine, Duke University School of Medicine, Durham, NC 27710.
  • Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC 27705.
  • Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599.

ORCID-Profile: W June Brickey, David L Caudell, Andrew N Macintyre, John D Olson, Sirui Li, J Daniel Bourland, Lisa M O'Donnell, Hao Guo, William C Zamboni, Gregory D Sempowski, J Mark Cline, Jenny P Y Ting

Förderung

  • NIAID NIH HHS
  • NCI NIH HHS
  • HHS | NIH | National Institute of Allergy and Infectious Diseases
  • DOD | USA | MEDCOM | Congressionally Directed Medical Research Programs
  • HHS | NIH | National Cancer Institute

Zitieren

APA

Brickey, W. J., Caudell, D. L., Macintyre, A. N., Olson, J. D., Dai, Y., Li, S., Dugan, G. O., Bourland, J. D., O'Donnell, L. M., Tooze, J. A., Huang, G., Yang, S., Guo, H., French, M. N., Schorzman, A. N., Zamboni, W. C., Sempowski, G. D., Li, Z., Owzar, K., …, & Ting, J. P. Y. (2023). The TLR2/TLR6 ligand FSL-1 mitigates radiation-induced hematopoietic injury in mice and nonhuman primates. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2122178120

Vancouver

Brickey WJ, Caudell DL, Macintyre AN, Olson JD, Dai Y, Li S, et al. The TLR2/TLR6 ligand FSL-1 mitigates radiation-induced hematopoietic injury in mice and nonhuman primates. Proceedings of the National Academy of Sciences. 2023. doi:10.1073/pnas.2122178120

BibTeX
@article{Brickey2023,
  author = {Brickey, W June and Caudell, David L and Macintyre, Andrew N and Olson, John D and Dai, Yanwan and Li, Sirui and Dugan, Gregory O and Bourland, J Daniel and O'Donnell, Lisa M and Tooze, Janet A and Huang, Guannan and Yang, Shuangshuang and Guo, Hao and French, Matthew N and Schorzman, Allison N and Zamboni, William C and Sempowski, Gregory D and Li, Zhiguo and Owzar, Kouros and Chao, Nelson J and Cline, J Mark and Ting, Jenny P Y},
  title = {The TLR2/TLR6 ligand FSL-1 mitigates radiation-induced hematopoietic injury in mice and nonhuman primates},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2023},
  doi = {10.1073/pnas.2122178120}
}
Kostenlos starten →